More Galleries
5 startups that are reimagining the world Bricks that grow from microorganisms, household garbage turned into art, three-wheeled bike-cars -- these startups are redefining urban living. More
Blue collar entrepreneurs These five entrepreneurs took their blue collar experience and used it to launch innovative businesses. More
7 lifehacks to eliminate your holiday hassle Whether curating the perfect gift or finding a pet-sitter, these startups offer time-saving services that might just seem like holiday magic. More

Special Offer
30 of 36
Stop the bleeding
Stop the bleeding
Bani Cipriano, Matthew Dowling and Peter Thomas
Team name: Remedium Technologies

School: University of Maryland, Robert H. Smith School of Business

Team Members: Matthew Dowling, Peter Thomas, Bani Cipriano, Oluwatosin Ogunsola, Akinola Dosunmu

Concept: Remedium Technologies is developing products designed to stop bleeding caused by injury or surgery. The company has two products in the works: a freeze-dried sponge, to be applied directly to a wound in order to control hemorrhaging; and a spray-on liquid to treat minor bleeding and seal tissue during surgical procedures.

Both products rely on a proprietary biopolymer-based material that gently adheres to tissue. The material comes off easily after the wound heals.

The sponge will be marketed to the U.S. military and hospital emergency rooms. The spray will be marketed to hospital surgical centers. Remedium believes its product is more effective than similar products currently on the market, and also cheaper to manufacture, giving the company a competitive edge.

Team members Dowling and Thomas are Ph.D. candidates studying bioengineering, with experience researching biopolymers. Ogunsola has a Ph.D. in chemical engineering and is a research associate at the U.S. Food and Drug Administration.

Timeline: The sponge and spray are currently undergoing pre-clinical testing on pigs, and the company has applied for a provisional patent for its biopolymer technology. The team estimates two years for product development and FDA approval. One year after the U.S. launch, the company plans to expand into Africa and South America, where inexpensive medical solutions are in demand, with help from government and philanthropic organizations. The company expects to be profitable by year three. -Stephenie Fletcher

NEXT: New help for diabetics

Last updated May 02 2008: 11:51 AM ET

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.